THE DIABETIC PERIPHERAL NEUROPATHIC PAIN IMPACT (DPNPI) MEASURE – PSYCHOMETRIC VALIDATION OF A NEW PATIENT REPORTED OUTCOME MEASURE

Author(s)

Brod M*1;Ramasamy A2;Bushnell DM3, Blum SI2 1The Brod Group, Mill Valley, CA, USA, 2Forest Research Institute, Jersey City, NJ, USA, 3Health Research Associates, Inc., Seattle, WA, USA

OBJECTIVES: The Diabetic Peripheral Neuropathic Pain Impact (DPNPI) Measure is a patient-reported outcome (PRO) measure developed in accordance with the FDA PRO guidance for assessing the impacts of living with Diabetic Peripheral Neuropathic Pain (DPNP). A validation study was conducted to evaluate the measurement model and properties of the 27-item draft version of the DPNPI. METHODS: A non-interventional, observational, survey-based validation study enrolled outpatients from clinical sites in the United States.  Recruitment included diagnosed DPNP patients (aged 18-80) both treated and untreated with prescription agents.  Subjects completed a retest survey via mail two weeks after their in-clinic assessment.  Analyses included assessment of the measurement model (factor analysis), reliability (internal consistency, test-retest) and validity (content, known-groups) of the DPNPI.  IRT was utilized to evaluate item fit and function.  RESULTS: Out of 124 subjects (56% male, mean age 62.8),105 completed the retest survey.  Nine items from the draft version were deleted due to conceptual issues and/or redundancy.  Factor analysis confirmed the three hypothesized domains: Physical/Mobility Function; Daily Life; Sleep. All domains and the total score were internally consistent (0.91 to 0.96) and reproducible (0.84 to 0.91). All a priori convergent validity hypotheses were confirmed (p<.001) with moderate-strong association between the total and/or subscale scores on the DPNPI measure and other logically related measures (range 0.43 to 0.79).   Additionally, all a priori hypothesized associations for content and known-group validity of domains and total score were confirmed (p<.001) and IRT fit statistics were within acceptable range.  CONCLUSIONS: The final 18-item version of the DPNPI can be considered a well-designed, valid and reliable measure of the impact of DPNP on patients’ daily lives and physical functioning.  This measure can be used as an endpoint in clinical trials to assess impacts related to DPNP.  Further study is needed to understand the responsiveness of the DPNPI.

Conference/Value in Health Info

2013-11, ISPOR Europe 2013, The Convention Centre Dublin

Value in Health, Vol. 16, No. 7 (November 2013)

Code

PDB87

Topic

Patient-Centered Research

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes

Disease

Diabetes/Endocrine/Metabolic Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×